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Background: Diabetes is a risk factor for the development of cardiovascular diseases with impaired angiogenesis.
We have previously shown that platelet-derived growth factor C (PDGF-C) and its receptor, PDGF receptor α
(PDGFR-α) were downregulated in ischemic limbs of diabetic mice, although the underlying mechanisms remained
elusive. Protein kinase C (PKC) is a family of serine/threonine kinases and is known to be involved in angiogenesis.
The purpose of this study is to elucidate the mechanisms of how PDGF-C/PDGFR-α axis is impaired in diabetes.
Methods: Human umbilical vein endothelial cells (HUVECs) and human cardiac microvascular endothelial cells
(HMVECs) cultured in normoglycemic or hyperglycemic conditions were examined. We also examined the effects of
PKC inhibition on the PDGF-C/PDGFR-α axis in endothelial cells exposed to hyperglycemia.
Results: Hyperglycemia inhibited proliferation and decreased viability of both HUVECs and HMVECs. Hyperglycemic
endothelial cells exhibited decreased PDGFR-α expression both at messenger RNA (mRNA) and protein levels, while
there was no significant change in expression of PDGF-C. We also found that expression of PKC-α, one of the PKC
isoforms, was increased in hyperglycemic endothelial cells and that inhibition of PKC upregulated PDGFR-α expression
in these cells. Phosphorylation of extracellular signal-regulated kinase (ERK) and Akt induced by PDGF-C was significantly
attenuated in hyperglycemic endothelial cells, whereas inhibition of PKC effectively reversed these inhibitory effects.
Moreover, inhibition of PKC also promoted angiogenesis induced by PDGF-C in hyperglycemic endothelial cells, which
was not observed in vascular endothelial growth factor-A (VEGF-A)-induced angiogenesis.
Conclusions: These findings suggest that downregulation of the PDGF-C/PDGFR-α axis is involved in impaired
angiogenesis of hyperglycemia through upregulation of PKC. Targeting PKC to restore PDGF-C signaling might
be a novel therapeutic strategy for the treatment of vascular complications in diabetes.
Keywords: Platelet-derived growth factor C (PDGF-C), Diabetes, Therapeutic angiogenesis, Protein kinase C (PKC),
Hyperglycemia, Endothelial cellsIntroduction
There are increasing numbers of patients who suffer
from ischemic cardiovascular diseases, and most of such
patients have some risk factors. Among them, diabetes is
known to have strong association with the development
of cardiovascular diseases [1,2]. Indeed, vascular com-
plications associated with diabetes may result from
atherosclerosis of large vessels, causing cardiac, cerebral
and peripheral vascular diseases [3,4]. Moreover, these* Correspondence: nferrara@ucsd.edu
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tory to conventional therapies, leading to increased mor-
bidity and mortality among patients of diabetes [5-7].
Thus, it is important to establish novel therapeutic mo-
dalities for these patients.
Therapeutic angiogenesis is a relatively new and promi-
sing concept for treating patients with ischemic cardiovas-
cular diseases [8-10]. It involves the use of angiogenic
growth factors to promote development of collateral arte-
ries. Vascular endothelial growth factor-A (VEGF-A) hasentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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dered as the key regulator of angiogenesis [11-14]. How-
ever, several lines of evidence have shown that the benefits
of this treatment are limited [15]. Indeed, the angiogenic
response after ischemia is attenuated in patients with dia-
betes, interfering with the response to treatment [16,17].
Moreover, it has recently been reported that a ligand-
independent VEGF receptor 2 (VEGFR2) signaling path-
way is activated in diabetic endothelial cells, leading to
impaired responses to exogenous VEGF-A and limited
angiogenic events [18,19]. Collectively, these studies
suggest that further basic research is needed to
elucidate the mechanisms of angiogenesis, especially in
diabetic state, to improve the overall outcome of thera-
peutic angiogenesis.
Platelet-derived growth factors (PDGFs) are potent
mitogenic and migratory factors for many cell types of
mesenchymal origin [20]. The PDGF family consists of
four different polypeptide chains encoded by four dif-
ferent genes: PDGF-A, PDGF-B, and the more recently
discovered PDGF-C and PDGF-D [21,22]. Among these,
PDGF-C has been known to promote angiogenesis inde-
pendently of VEGF-A [23]. Actually, inhibition of PDGF-C
leads to reduced angiogenesis in experimental tumors re-
fractory to anti-VEGF treatment [24] or to suppression of
both choroidal and retinal neovascularization [25]. More-
over, PDGF-C has been reported to revascularize ischemic
tissues by mobilizing endothelial progenitor cells or stimu-
lating migration of endothelial cells [26]. We also have re-
cently found that expression of PDGF-C and its receptor,
PDGF receptor α (PDGFR- α) was downregulated in ische-
mic limb tissues of diabetic mice, possibly contributing to
impaired angiogenesis of diabetes. Moreover, introduction
of PDGF-C significantly promoted revascularization in
these mice [27]. Collectively, these studies suggest that
PDGF-C may be an interesting candidate for therapeutic
angiogenesis. However, the underlying mechanisms of
how PDGF-C/PDGFR-α axis is impaired in diabetes still
remain to be elucidated.
Therefore, we sought to investigate such mechanisms by
using human endothelial cells (ECs) exposed to hypergly-
cemic condition. Hyperglycemia inhibited cell prolifera-
tion and decreased cell viability, which is in agreement
with a previous study [28]. Moreover, we found that the
expression of PDGFR-α was downregulated in hypergly-
cemic ECs both at mRNA and protein levels. We also
found that upregulation of protein kinase C (PKC)-α ex-
pression was involved in decreased PDGFR-α expression
in hyperglycemic ECs. Consistent with this finding, inhibi-
tion of PKC led to augmentation of intracellular signaling
induced by PDGF-C, resulting in promotion of angioge-
nesis in hyperglycemic ECs. These findings suggest that
downregulation of the PDGF-C/PDGFR-α axis is involved
in impaired angiogenesis of diabetes through upregulationof PKC. Targeting PDGF-C and PKC might be a novel
strategy for therapeutic angiogenesis in the diabetic state.
Materials and methods
Reagents
Recombinant human VEGF-A and PDGF-C were from
Peprotech (Rocky Hill, NJ) and Sigma-Aldrich (St. Louis,
MO), respectively. D-mannitol and d-glucose were from
Sigma-Aldrich. Trypan blue solution was from GE
Healthcare Life Sciences (Little Chalfont, UK). Bisindo-
lylmaleimide I (Bis I) was purchased from Cell Signaling
Technology (Danvers, MA). Sulforaphane was from Tre-
vigen (Gaithersburg, MD).
Cells
Human umbilical vein endothelial cells (HUVECs), hu-
man cardiac microvascular endothelial cells (HMVECs),
and human aortic smooth muscle cells (AoSMCs) were
purchased from Lonza (Walkersville, MD). HUVECs
were grown in EGM-2 medium (Lonza), HMVECs in
EGM-2-MV medium (Lonza), and AoSMCs in SmGM-2
medium (Lonza) on gelatin-coated tissue culture dishes
(BD Bioscience, Becton, NJ), respectively. Cells from
fewer than 5 generations were used for all experiments.
High-glucose cultures were grown in the presence of 30
mM glucose for a minimum of 5 days and then subjected
to further analysis. The total cell numbers were calculated
by a Countess automated cell counter (Life Technologies,
Carlsbad, CA). For signaling pathway analysis and tube
formation analysis, HUVECs were serum-starved for 15
hours in EBM-2 medium (Lonza) supplemented with 0.1%
fetal bovine serum (Omega Scientific, Tarzana, CA) before
being treated with test substances.
RNA analysis
Total RNA was extracted by an RNeasy Plus Mini kit
(Qiagen, Valencia, CA) according to the manufacturer’s
instructions. cDNA was prepared using High Capacity
cDNA Reverese Transcription Kits (Life Technologies).
Quantitative real-time polymerase chain reaction (PCR)
was performed by the ViiA7 Real-Time PCR system
(Life Technologies) with the Taqman Gene Expression
Assays and the Taqman Fast Advanced Master Mix (Life
Technologies). Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) messenger RNA was used as an endo-
genous control for quantitative real-time PCR analyses. At
least three biological replicates were included in each
analysis.
Western blot analysis
Whole cell lysates were prepared in RIPA buffer
(Thermo Scientific, Rockford, IL) with Halt Protease and
Phosphatase Inhibitor Cocktail (Thermo Scientific). The
lysates (20 to 40 μg) were resolved by SDS-PAGE. The
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difluoride membrane (Bio-Rad, Hercules, CA) and incu-
bated with the primary antibody followed by anti-rabbit
IgG-horseradish peroxidase antibody or anti-mouse IgG-
horseradish peroxidase antibody (GE Healthcare, Little
Chalfont, UK). Specific proteins were detected by the en-
hanced chemiluminescent substrate (Thermo Scientific).
The primary antibodies used for Western blotting were as
follows: anti-PDGFRα antibody (951, sc-431), anti-PKCα
antibody (C-20, sc-208), anti-PKCβΙΙ antibody (C-18,
sc-210), anti-PKCδ antibody (C-17, sc-213) (Santa Cruz
Biotechnology, Santa Cruz, CA), anti-phospho-extracellular
signal-regulated kinase (ERK) antibody (20G11, #4376),
anti-ERK antibody (137F5, #4695), anti-phospho-Akt anti-
body (D9E, #4060), anti-Akt antibody (C67E7, #4691)
(Cell Signaling Technology), and anti-β-actin antibody
(AC-74, A2228) (Sigma-Aldrich).
Tube formation assay
The tube formation assay was performed using a commer-
cially available kit (In Vitro Angiogenesis Tube Formation
Assay Kit, Trevigen, #3470-096-K) according to the manu-
facturer’s instructions. Briefly, growth factor-reduced base-
ment membrane extract solution in a 96-well plate was
allowed to form a reconstituted matrix for one hour at
37°C. HUVECs were seeded at 1.5 × 104 per well and
cultured for up to 24 hours in the presence or absence of
different kinds of test substances. Capillary-like tube for-
mation was assessed by photography under a stereoscopic
microscope (Zeiss, Oberkochen, Germany) at a ×80 mag-
nification. Total tube length was analyzed by using Image
J software (NIH, Bethesda, MD).
Statistical analysis
The data are shown as means ± standard error of the
mean. Differences between two groups were analyzed by
a two-sided Student t-test. One-way analysis of variance
(ANOVA) was used for multiple group comparison fol-
lowed by the Bonferroni procedure for comparison of
means. All experiments were repeated at least three
times. In all analyses, P values of < 0.05 were considered
statistically significant.
Results
Hyperglycemia inhibits cell proliferation and decreases
cell viability of endothelial cells
We first examined the effect of hyperglycemia on pro-
liferation and viability of endothelial cells (ECs). Since we
confirmed that the total number of cells and the ratio of
cells positive for trypan blue staining exposed to 24.5 mM
d-mannitol in normoglycemic (5.5 mM d-glucose) condi-
tions were not different from those in control cultures
(Additional file 1: Figure S1), we used 24.5 mM d-mannitol
as an osmotic control for in all further experiments. Weexamined two types of human EC; human umbilical vein
endothelial cells (HUVECs) and human cardiac micro-
vascular endothelial cells (HMVECs). We plated HUVECs
and HMVECs in normoglycemic or hyperglycemic (30 mM
d-glucose) conditions and cultured them for 5 days. As
shown in Figure 1A, HUVECs or HMVECs cultured for 5
days in such hyperglycemic condition showed reduced in-
creases in total cell numbers, compared to normoglycemic
conditions. Moreover, the ratio of cells positive for trypan
blue staining, which are thought to be dead cells, was sig-
nificantly increased in HUVECs and HMVECs cultured in
hyperglycemic condition (Figure 1B). These results sug-
gest that hyperglycemia inhibits cell proliferation and de-
creases cell viability of ECs.
Expression of PDGFR-α is downregulated in
hyperglycemic endothelial cells
We have previously reported that expression of PDGF-C
or PDGFR-α after ischemia is decreased in diabetic mice,
leading to impaired angiogenesis [27]. Thus, we sought to
examine messenger RNA (mRNA) levels of these an-
giogenic factors in hyperglycemic ECs (HUVECs and
HMVECs) by quantitative real-time PCR (qRT-PCR) ana-
lysis. We found that compared to normoglycemic condi-
tions, expression of PDGFR-α was markedly decreased in
hyperglycemic ECs (Figure 2A). VEGFR2 expression was
also modestly decreased in hyperglycemic ECs, although
we did not observe any differences in PDGF-C or VEGF-
A expression compared to normoglycemia (Figure 2A).
After confirming that PDGFR-α expression was almost
comparable in normoglycemic ECs treated with or without
24.5 mM d-mannitol (Additional file 2: Figure S2A, B), we
performed Western blot analysis to examine the protein ex-
pression of PDGFR-α in hyperglycemic ECs. Consistent
with our qRT-PCR results, the expression of PDGFR-α in
hyperglycemic ECs was markedly decreased compared to
normoglycemic, mannitol-treated ECs (Figure 2B, C).
These results indicate that the expression of PDGFR-α is
downregulated in hyperglycemic ECs both in mRNA and
protein levels.
Upregulation of PKC leads to decreased PDGFR-α
expression in hyperglycemic endothelial cells
Hyperglycemia has been reported to activate members
of the protein kinase C (PKC) family, some of which are
implicated in angiogenesis [29]. We hypothesized that
PKC might be implicated in the decreased expression of
PDGFR-α in hyperglycemic ECs. To test this hypothesis,
we first examined the expression of PKC-α, PKC-βΙΙ,
and PKC-δ, which are known to be expressed in ECs
[30]. Because HUVECs and HMVECs showed the same
tendency toward the total number of cells, ratio of cells
positive for trypan blue staining, and expression of
PDGFR-α exposed to hyperglycemic conditions (Figures 1, 2),
Figure 1 Effects of hyperglycemia on endothelial cells. A: HUVECs or HMVECs were treated with 5.5 mM (Low) or 30 mM (High) glucose and
total cell numbers were calculated. *P < 0.05 vs Low glucose (n = 4 for each group). Data represent means ± standard error of the mean. B: Ratio
of trypan blue positive HUVECs or HMVECs treated with 5.5 mM (Low) or 30 mM (High) glucose. *P < 0.05 vs Low glucose (n = 4 for each group).
Data represent means ± standard error of the mean.
Moriya and Ferrara Cardiovascular Diabetology  (2015) 14:19 Page 4 of 10and considering that HUVECs have been widely used to
elucidate molecular mechanisms of diabetic state in ECs
[31,32], we used only HUVECs for further experiments.
We found that hyperglycemia significantly upregulated the
protein expression of PKC-α in HUVECs (Figure 3A, B).
On the other hand, the expression of PKC-βΙΙ or PKC-δ
was not significantly different between normoglycemic
and hyperglycemic ECs (Figure 3B), although we could not
exclude the possibility that these isoforms were still acti-
vated in hyperglycemia. Next, we investigated the effects
of inhibition of PKC. We treated normoglycemic and
hyperglycemic HUVECs with bisindolylmaleimide I (Bis I),
an inhibitor of PKC [33], and examined the expression of
PKC-α and PDGFR-α by Western blot analysis. Consistent
with previous obsevations [34], we confirmed that treat-
ment with Bis I significantly downregulated the expression
of PKC-α both in normoglycemic and hyperglycemic
HUVECs (Figure 3C, D). Interestingly, downregulation of
PDGFR-α expression was completely abolished by treat-
ment with Bis I in hyperglycemic ECs (Figure 3C, D). We
also confirmed that the effect of Bis I had some dose-
dependent tendency to the reduced expression of PKC-α,although it was not statistically significant (Additional
file 3: Figure S3A). Moreover, we found that longer ex-
posure to Bis I significantly upregulated the expression of
PDGFR-α even in normoglycemic ECs (Additional file 3:
Figure S3B). These results suggest that upregulation of
PKC expression induced by hyperglycemia is involved in
the downregulation of PDGFR-α expression in HUVECs.
Inhibition of PKC leads to increased intracellular signaling
induced by PDGF-C in endothelial cells
Next we investigated whether downregulation of PDGFR-α
in hyperglycemic ECs actually affects downstream sig-
naling induced by PDGF-C. We found that PDGF-C-
induced phosphorylation of Akt and ERK, both of which
are crucial kinases in the intracellular signaling pathway
for this growth factor, was abolished in hyperglyce-
mic HUVECs, which is in contrast to normoglycemic
HUVECs (Figure 4A, B). However, pretreatment with Bis I
significantly increased phosphorylation of Akt in hypergly-
cemic HUVECs and phosphorylation of ERK in hypergly-
cemic and normoglycemic HUVECs following PDGF-C
stimulation (Figure 4A, B). We also observed decreased
Figure 2 Expression of PDGFR-α is downregulated in hyperglycemic endothelial cells. A: PDGFR-α, PDGFR-β, VEGFR2, PDGF-C, and VEGF-A
mRNA levels in HUVECs or HMVECs treated with 5.5 mM (Low) or 30 mM (High) glucose were assessed by quantitative real-time PCR. *P < 0.05,
**P < 0.01 vs Low glucose HUVECs (n = 6 for each group). #P < 0.05, ##P < 0.01 vs Low glucose HMVECs (n = 6 for each group). Data represent
means ± standard error of the mean. B: Western blot analysis of PDGFR-α expression in HUVECs treated with 5.5 mM (Low) or 30 mM (High)
glucose. Relative quantification data are also shown (right). **P < 0.01 vs Low glucose (n = 6 for each group). Data represent means ± standard
error of the mean. C: Western blot analysis of PDGFR-α expression in HMVECs treated with 5.5 mM (Low) or 30 mM (High) glucose. Relative
quantification data are also shown (right). ##P < 0.01 vs Low glucose (n = 8 for each group). Data represent means ± standard error of the mean.
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hyperglycemic HUVECs (Additional file 4: Figure S4).
However, unlike PDGF-C, treatment with Bis I inhyperglycemic HUVECs did not increase phosphorylation
of Akt or ERK induced by VEGF-A (Additional file 4:
Figure S4). Moreover, tretament with Bis I significantly
Figure 3 Upregulation of PKC leads to decreased PDGFR-α expression in hyperglycemic endothelial cells. A: Western blot analysis of
PKC-α in HUVECs treated with 5.5 mM (Low) or 30 mM (High) glucose. B: Relative quantification data of Western blot analysis of PKC-α, PKC-βII,
and PKC-δ in HUVECs treated with 5.5 mM (Low) or 30 mM (High) glucose. **P < 0.01 vs Low glucose (n = 4 for each group). Data represent
means ± standard error of the mean. C: HUVECs exposed to 5.5 mM (Low) or 30 mM (High) glucose were treated with or without bisindolylmaleimide
I (Bis I) at a concentration of 4 μΜ for 30 minutes and then were subject to Western blot analysis for PKC-α and PDGFR-α expression. D: Relative
expression levels of PKC-α and PDGFR-α in the experiment of Figure 3C. *P < 0.05, **P < 0.01 vs Low glucose, Bis I (−) group. #P < 0.05, ##P < 0.01 vs
High glucose, Bis I (−) group. n = 4 for each group. Data represent means ± standard error of the mean.
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ERK in normoglycemic HUVECs (Additional file 4:
Figure S4). Collectively, these results suggest that inhi-
bition of PKC could potentiate the intracellular signaling
induced by PDGF-C, but not VEGF-A, in hyperglycemic
HUVECs.Inhibition of PKC promotes angiogenesis induced by
PDGF-C, but not VEGF-A, in hyperglycemic endothelial cells
To investigate the effects of PKC inhibition on angiogen-
esis, we performed tube formation assays using HUVECs
in normoglycemic and hyperglycemic conditions. Sulfo-
raphane was used as a negative control for the assays.
Figure 4 Inhibition of PKC potentiates intracellular signaling induced by PDGF-C in endothelial cells. A: HUVECs exposed to 5.5 mM (Low)
or 30 mM (High) glucose were treated with PDGF-C (50 ng/mL) or PDGF-C + Bis I (4 μΜ) and analyzed for signaling molecules by Western blot
analysis. B: Relative expression levels of pERK and pAkt in the experiment of Figure 4A. Results are shown as the ratio of pAkt to Akt densities,
and pERK to ERK densities, respectively. *P < 0.05, **P < 0.01 vs PDGF-C (−), Bis I (−) group. #P < 0.05, ##P < 0.01 vs PDGF-C (+), Bis I (−) group.
n = 4 for each group. Data represent means ± standard error of the mean.
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markedly increased tube formation in normoglycemic
HUVECs, while this increase was blunted but still sig-
nificant in hyperglycemic HUVECs (Figure 5A-C).
Intriguingly, treatment with Bis I significantly augmen-
ted PDGF-C-induced tube formation in hyperglycemic
HUVECs (Figure 5B, C). However, treatment with Bis I
did not increase or even significantly decreased VEGF-A-
induced tube formation (Figure 5A-C). Treatment with
Bis I alone did not affect tube formation, both in nor-
moglycemic and hypeglycemic HUVECs (Figure 5A-C).
These results suggest that PKC inhibition promotes
angiogenesis induced by PDGF-C, but not VEGF-A, inhyperglycemic HUVECs possibly by upregulating PDGF-C/
PDGFR-α axis.
Discussion
PDGFs have a variety of effects in many cell types. Among
the four members of the PDGF family, PDGF-B and
PDGF-C have been extensively characterized for their role
in vessel maturation and growth. While PDGF-B requires
other angiogenic factors like VEGF-A to induce neovascu-
larization, PDGF-C has the potential to promote revascu-
larization after ischemia, independently of other factors
[23,26]. Moreover, we recently reported that expression of
PDGF-C or PDGFR-α was downregulated in ischemic
Figure 5 Inhibition of PKC promotes angiogenesis induced by PDGF-C, but not VEGF-A, in hyperglycemic endothelial cells.
A, B: Photographs show tube formation in HUVECs exposed to 5.5 mM (Low) (A) or 30 mM (High) (B) glucose in the presence of Bis I (4 μΜ),
PDGF-C (50 ng/mL), PDGF-C + Bis I, VEGF (50 ng/mL), VEGF + Bis I, and VEGF + Sulforaphane (5 μΜ). PBS treatment served as control (Control).
Sulforaphane was used as a negative control for the assay. Scale bar = 300 μm. C: Total tube length was analyzed in the experiment of Figure 5A (left)
and 5B (right). *P < 0.05, **P < 0.01 vs Control (VEGF(−), PDGF-C(−), Bis I(−), and Sulforaphane(−)) group. ##P< 0.01 vs VEGF(+), PDGF-C(−), Bis I (−), and
Sulforaphane (−) group. †P < 0.05 vs VEGF(−), PDGF-C(+), Bis I (−), and Sulforaphane (−) group. n = 5 ~ 9 for each group. Data represent means ± standard
error of the mean.
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flow recovery after ischemia [27]. Also, a recent study re-
ported that PDGF signaling is critically involved in the
pathogenesis of diabetes [35]. On the other hand, a clinical
study revealed that there were no significant differences in
the serum concentrations of VEGF between control sub-
jects and diabetic patients [36]. Taken together, these fin-
dings support the hypothesis that PDGF-C might be apromising new target for the treatment of vascular com-
plications related to diabetes.
The present study sought to investigate how the
PDGF-C/PDGFR-α axis is downregulated using cultured
human ECs exposed to hyperglycemia. We found that
hyperglycemia led to inhibition of cell proliferation, de-
creased cell viability, and reduced angiogenic responses
to VEGF-A in ECs (Figures 1A-B, 5A-C). These results
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betic mice showing reduced blood flow recovery and
neovascularization after ischemia even with introduction
of VEGF-A [27,31].
We also show here that expression of PDGFR-α was
significantly downregulated in hyperglycemic ECs, while
expression of PDGF-C was almost unchanged between
normoglycemic and hyperglycemic ECs (Figure 2A). On
the other hand, we found that expression of PDGF-C
was significantly downregulated both at baseline and
after ischemia in limb tissues of diabetic mice in our
previous in vivo study [27]. Since in vivo murine limb
tissues contain various cell types besides ECs such as
vascular smooth muscle cells, fibroblasts, and skeletal
muscle cells, it is possible that decreased PDGF-C expres-
sion occurs in cell types other than ECs in diabetic limbs.
Indeed, we observed that the expression of PDGF-C was
decreased in hyperglycemic human aortic smooth muscle
cells (AoSMCs) in vitro (data not shown), suggesting that
SMCs might be more responsible for the decreased
expression of PDGF-C in vivo as well. Further studies are
required to identify the cellular localization of the
decreased PDGF-C and/or PDGFR-α expression in vivo.
Our results also suggest that PKC is critically involved
in the decreased PDGFR-α expression in hyperglycemic
ECs. We found that expression of PKC-α was signifi-
cantly upregulated in hyperglycemic ECs (Figure 3A, B).
PKC is a member of a large family of serine/threonine
kinases and is known to be involved in angiogenesis
[37]. Moreover, PKC is also implicated in the increased
risk of atherosclerosis in diabetes [38]. However, the role
of PKC for angiogenesis still remains elusive because the
effect of PKC on angiogenesis seems to be different or
even opposite depending on PKC isoforms [39]. More-
over, there are some conflicting reports indicating that
PKC-α promotes [40,41] or inhibits [42] angiogenic
activity of ECs, and it has been known that inhibition of
PKC leads to suppression of VEGF release from platelets
[43]. We show here that inhibition of PKC by Bis I leads
to increased PDGFR-α expression, resulting in poten-
tiation of intracellular signaling, and augmentation of
angiogenesis induced by PDGF-C, but not by VEGF-A
(Figures 3, 4, 5). Based on these findings, we speculate
that the complexity and apparent discrepancies in the
effects of PKC on angiogenesis stem not only from
different PKC isoforms but also from downstream mo-
lecular targets of PKC in ECs. Further studies are needed
to confirm whether PKC differentially regulates angio-
genesis induced by PDGF-C and VEGF-A signaling, in
addition to the effects of specific inhibition or activation
of PKC-α on angiogenesis induced by PDGF-C in the
diabetic state.
In summary, the present study shows that downregula-
tion of PDGF-C/PDGFR-α axis is involved in impairedendothelial cell functions in hyperglycemia at least in
part through upregulation of PKC. Therefore, targeting
PKC to restore PDGF-C signaling might be anovel thera-
peutic option for the treatment of vascular complica-
tions in diabetic patients.
Additional files
Additional file 1: Figure S1. Effects of mannitol on HUVECs. HUVECs
were treated with d-mannitol at the concentration of 24.5 mM in
normoglycemic (5.5 mM glucose) conditions for 5 days (Mannitol). Total
cell number of (left) and the ratio of cells positive for trypan blue (right)
were analyzed. HUVECs cultured in normoglycemic conditions served as
control (Control). n=5 for each group. Data represent means ± standard
error of the mean.
Additional file 2: Figure S2. Treatment with mannitol does not affect
expression of PDGFR-α in endothelial cells. A: HUVECs were treated with
or without 24.5 mM d-mannitol in normoglycemic conditions and then
subjected to Western blot analysis for PDGFR-α. Relative quantification
data are also shown (right). n=3 for each group. Data represent means ±
standard error of the mean. B: HMVECs were treated with or without
24.5 mM d-mannitol in normoglycemic condition and then subjected to
Western blot analysis for PDGFR-α. Relative quantification data are also
shown (right). n=3 for each group. Data represent means ± standard
error of the mean.
Additional file 3: Figure S3. Effect of PKC inhibition on expression of
PKC-α and PDGFR-α in endothelial cells. A: HUVECs exposed to 5.5 mM
(Low) or 30 mM (High) glucose were treated or not bisindolylmaleimide
I (Bis I) at the concentration of 2 or 4 μΜ for 30 minutes and then were
subject to Western blot analysis for PKC-α and PDGFR-α expression.
Relative expression levels of PKC-α and PDGFR-α are shown. *P<0.05 vs
Low glucose, Bis I (-) group. ##P<0.01 vs High glucose, Bis I (-) group. n=4
for each group. Data represent means ± standard error of the mean.
B: HUVECs exposed to 5.5 mM (Low) or 30 mM (High) glucose were
treated with or without Bis I at a concentration of 4 μΜ for 120 minutes
and then were subject to Western blot analysis for PKC-α and PDGFR-α
expression. Relative expression levels of PKC-α and PDGFR-α are shown.
*P<0.05, **P<0.01 vs Low glucose, Bis I (-) group. #P<0.05, ##P<0.01 vs
High glucose, Bis I (-) group. n=4 for each group. Data represent means ±
standard error of the mean.
Additional file 4: Figure S4. Effects of PKC inhibition on intracellular
signaling induced by VEGF-A in normoglycemic or hyperglycemic
endothelial cells. HUVECs exposed to 5.5 mM (Low) or 30 mM (High)
glucose were treated with VEGF-A alone (50 ng/mL) or VEGF-A + Bis I
(4 μΜ) and analyzed for the VEGF-A signaling pathways by Western blot
analysis. Relative expression levels of pERK and pAkt are shown as the
ratio of pAkt to Akt densities, and pERK to ERK densities, respectively.
*P<0.05, **P<0.01 vs VEGF-A (-), Bis I (-) group. #P<0.05 vs VEGF-A (+),
Bis I (-) group. n=5~6 for each group. Data represent means ± standard
error of the mean.
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